期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 116, 期 51, 页码 25389-25391出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1916144116
关键词
endometriosis; repurposing; dichloroacetate; glycolysis
资金
- Wellbeing of Women (PwC) [R42533]
- Medical Research Council [MR/N024524/1, MR/N022556/1]
- MRC [MR/P00265X/1, MR/N022556/1, MR/N024524/1, 1789503, MR/M009238/2] Funding Source: UKRI
Endometriosis is a chronic pain condition affecting similar to 176 million women worldwide. It is defined by the presence of endometrium-like tissue (lesions) outside the uterus, most commonly on the pelvic peritoneum. There is no cure for endometriosis. All endometriosis drug approvals to date have been contraceptive, limiting their use in women of childbearing age. We have shown that human peritoneal mesothelial cells (HPMCs) recovered from the pelvic peritoneum of women with endometriosis exhibit significantly higher glycolysis, lower mitochondrial respiration, decreased enzymatic activity of pyruvate dehydrogenase (PDH), and increased production of lactate compared to HPMCs from women without disease. Transforming growth factor-beta 1 (TGF-beta 1) is elevated in the peritoneal fluid from women with endometriosis, and exposure of HPMCs to TGF-beta 1 exacerbates this abnormal phenotype. Treatment of endometriosis HPMCs with the pyruvate dehydrogenase kinase (PDK) inhibitor/PDH activator dichloroacetate (DCA) normalizes HPMC metabolism, reduces lactate secretion, and abrogates endometrial stromal cell proliferation in a coculture model. Oral DCA reduced peritoneal fluid lactate concentrations and endometriosis lesion size in a mouse model. These findings provide the rationale for targeting metabolic processes as a noncontraceptive treatment for women with endometriosis either as a primary nonhormonal treatment or to prevent recurrence after surgery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据